Hexarelin vs tesamorelin: what the evidence actually shows

Last updated 2026-07-24

What is the basic difference between hexarelin and tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone releasing hormone (GHRH). It binds the GHRH receptor on the pituitary and stimulates a fairly physiologic pulse of growth hormone release. It's sold under the brand name Egrifta (and Egrifta SV), and it is FDA-approved for one specific indication: reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy ^[1]. Hexarelin is a synthetic growth hormone secretagogue in the growth hormone releasing peptide (GHRP) family. It works through a different receptor, the ghrelin/GH secretagogue receptor, and it's a much more potent GH releaser milligram for milligram than the older GHRP compounds. It has never gone through FDA phase 3 trials for any indication and carries no approval anywhere in the world for human therapeutic use. That one fact, approved drug versus unapproved research compound, is the difference that matters most before you even get to dosing or side effects. Recent reviews of injectable peptides used in sports medicine and orthopaedics group both compounds under the broader GH-secretagogue category, but they consistently flag that the human trial evidence for GHRPs like hexarelin is thin compared to GHRH analogues with formal drug development programs ^[2][3].

Is tesamorelin FDA-approved and is hexarelin approved for anything?

Yes, tesamorelin is FDA-approved. It cleared phase 3 testing and is listed in the Drugs@FDA database under the brand names Egrifta and Egrifta SV, approved specifically for reducing visceral adipose tissue in HIV patients with lipodystrophy ^[4]. That's a narrow indication. It is not approved for general fat loss, bodybuilding, anti-aging use, or GH deficiency in people without HIV-associated lipodystrophy. Hexarelin has no FDA approval, full stop. There's no Drugs@FDA listing, no approved labeling, no indication. It shows up in the compounding-substance conversation instead: FDA maintains lists of bulk drug substances that can legally be used in 503A and 503B compounding, and evaluates nominated substances against safety and effectiveness data before allowing that use ^[5][6][7]. Being nominated for a bulks list is not the same thing as being approved as a drug, and it doesn't mean the substance has cleared any efficacy bar. This distinction is why an article comparing the two isn't really a fair fight on paper. One has passed the FDA's evidentiary bar for a specific use. The other hasn't been tested at that level in humans at all.

What does the clinical trial evidence show for each?

Tesamorelin's evidence base is genuinely substantial for its narrow indication. The core work is a pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials in HIV-infected patients with excess abdominal fat, which included safety extension data and established the visceral fat reduction that led to approval ^[8]. Since then the compound has been studied in a randomized trial for non-alcoholic fatty liver disease in HIV, showing effects on hepatic fat ^[9], in studies linking visceral fat reduction to improved liver enzymes ^[10], in research on inflammatory markers tied to visceral adipose reduction ^[11], and even in a 2025 trial looking at neurocognitive outcomes in people with HIV and abdominal obesity ^[12]. A newer meta-analysis of randomized controlled trials pooled body composition, hepatic fat, and metabolic outcomes across the tesamorelin trial base ^[13]. There's also population pharmacokinetic modeling specific to HIV-infected patients and healthy subjects ^[14], and post hoc analysis looking at whether baseline dorsocervical fat changes the treatment response ^[15]. Hexarelin has nothing comparable. There is no phase 3 trial, no FDA safety extension study, no pooled multicenter placebo-controlled dataset. What exists is scattered early-phase and mechanistic work, some of it decades old, mostly in small cohorts or animal models, looking at GH release kinetics rather than any approved clinical endpoint. Review articles covering peptide therapy in sports medicine note this gap explicitly when discussing GHRPs as a class, contrasting them with compounds that have completed formal regulatory review ^[2][3]. If you're the kind of person who reads primary literature before making a decision, the tesamorelin folder is thick. The hexarelin folder is thin.

How do hexarelin and tesamorelin compare on mechanism and expected effects?

What is tesamorelin actually approved to treat, and does that include general fat loss?

Tesamorelin is approved for one thing: reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy ^[4]. That's it. It is not approved for weight loss in people without HIV, not approved for subcutaneous fat reduction, not approved for anti-aging GH support, and not approved for athletic performance. A 2021 study did find that tesamorelin improves fat quality independent of changes in fat quantity, meaning some metabolic benefit showed up even when total fat mass didn't move much ^[16]. That's an interesting mechanistic finding, but it's still inside the HIV lipodystrophy trial population, not a general population. Any use of tesamorelin outside the HIV-lipodystrophy indication, including for general visceral fat reduction in metabolically healthy adults, is off-label. Off-label prescribing is legal and common in medicine, but it means the specific numbers from the original approval trials (which were run in HIV patients with lipodystrophy) don't automatically transfer to a different population. If you're considering it for that reason, read the tesamorelin evidence page and talk to a prescriber about what the trial population actually looked like versus your own situation.

What are the side effects and safety differences between the two?

Tesamorelin's safety profile is described in detail because of its phase 3 safety extension data ^[8]. Reported issues across the trial literature include injection site reactions, joint pain and stiffness (arthralgia), swelling from fluid retention, and effects on glucose metabolism, since raising GH/IGF-1 can reduce insulin sensitivity in some patients. Reviews covering its clinical use in HIV-associated lipodystrophy walk through this risk profile alongside the efficacy data ^[17][18][19]. Because it stimulates a GH pulse rather than delivering GH itself, the excess-GH risks (like acromegaly-type changes) are considered lower than with direct rhGH, but they aren't zero, and monitoring IGF-1 during treatment is standard practice. Hexarelin's safety data is comparatively sparse. What's published tends to come from smaller studies, older investigational-drug literature, or animal and mechanistic work rather than a phase 3 safety database. That's not the same as saying it's proven dangerous, but the honest answer is that nobody has the equivalent long-term human safety dataset that exists for tesamorelin. A recent safety-and-efficacy review of approved and unapproved peptide therapies used for musculoskeletal and athletic purposes flags exactly this asymmetry: some peptides in this space have real trial-based safety data, others are being used with far less human evidence behind them ^[20]. For a full rundown of documented tesamorelin side effects, see tesamorelin peptide side effects.

How do dosing protocols compare?

Tesamorelin's FDA-approved dosing is a once-daily subcutaneous injection, with the drug supplied as a lyophilized powder that requires reconstitution before injection. Population pharmacokinetic modeling in HIV-infected patients and healthy subjects has characterized how the drug clears and behaves at that approved dose ^[14], which is part of why the labeling is as specific as it is. Hexarelin doesn't have an FDA-approved dose because it doesn't have FDA approval. Any dosing information circulating for hexarelin comes from research protocols, anecdotal use, or extrapolation from its GH-releasing potency in small studies, not from a regulatory-reviewed label. That's a meaningful practical difference: with tesamorelin you can point to an approved dose and a pharmacokinetic dataset behind it; with hexarelin you're relying on informal sources. If you want the specifics on tesamorelin's approved dosing schedule, reconstitution steps, and how clinicians calculate dose by body weight, see tesamorelin dosage, the tesamorelin dosage calculator, and tesamorelin reconstitution.

Does hexarelin or tesamorelin help with liver fat or metabolic markers?

Tesamorelin has direct trial data here. A randomized, double-blind, multicenter trial specifically tested tesamorelin's effects on non-alcoholic fatty liver disease in HIV patients ^[9]. Separate research has looked at hepatic transcriptomic signatures in HIV-associated NAFLD after tesamorelin treatment ^[21], and a targeted proteomic and transcriptomic approach has tried to map out the biological pathways behind that liver response ^[22]. Visceral fat reduction from tesamorelin has also been tied to improved liver enzymes in HIV patients ^[10]. Hexarelin doesn't have a comparable trial in liver fat or NAFLD outcomes. Whatever effect it might have on hepatic fat through GH stimulation is theoretical, extrapolated from GH physiology generally, not demonstrated in a dedicated RCT the way tesamorelin's has been. If liver fat or metabolic markers are your actual concern, the evidence points clearly toward tesamorelin as the studied option, understanding again that the studied population is HIV-associated lipodystrophy, not the general public.

Can either be detected on a drug test, and is either banned in sport?

Both fall under anti-doping scrutiny as GH-axis stimulators. Research on detecting GHRH synthetic analogs and related secretagogues has specifically worked on improving methods to catch these compounds in doping-control testing, treating them as a detection challenge distinct from natural GH ^[23]. That paper covers the broader class of GHRH-type synthetic analogs, which is directly relevant to tesamorelin's mechanism, and the detection challenge exists precisely because these are potent, deliberately-designed molecules meant to trigger endogenous GH release. Hexarelin, as a GHRP-class secretagogue, falls into the same general anti-doping concern category, since anything that meaningfully raises GH or IGF-1 through a non-natural route is the kind of substance sports anti-doping labs try to detect. Athletes should assume both are prohibited substances in any tested sport and should not treat lack of a specific named test as safety.

Which one has better real-world sourcing and quality control?

Tesamorelin, as an FDA-approved product, has a manufacturing and quality chain that runs through standard pharmaceutical regulatory oversight, plus the option of pharmacy compounding under section 503A of the federal drug compounding statute when a compounded version is used ^[24], with bulk substances for that compounding governed by the FDA's 503A and 503B bulk substance lists ^[5][6][7]. That doesn't mean every compounded batch is identical to Egrifta, but there's a defined regulatory pathway with named oversight. Hexarelin sourcing runs almost entirely through research-chemical sellers and informal peptide vendors, with no FDA-approved manufacturing standard to check against and no drug label defining purity specs, since it isn't classified as an approved drug. That's the practical sourcing risk: you can't verify a hexarelin vial against an FDA reference standard the way you can (imperfectly) compare a tesamorelin product against Egrifta's approved specifications. For real numbers on what legitimate, provider-reviewed tesamorelin costs and how pricing breaks down between brand and compounded options, see tesamorelin cost. If you're going the tesamorelin route at all, sourcing through a provider-reviewed pathway, the kind Tesamorelin Co points readers toward with a named fulfilling pharmacy partner, is the sane way to avoid the quality-control gap that pure research-chemical purchasing carries.

So which one should you actually consider, hexarelin or tesamorelin?

If you have HIV-associated lipodystrophy with excess visceral fat, tesamorelin is the option with an FDA approval, phase 3 trial data, and a defined safety profile behind it ^[4][8]. That's not a close call. It's the only one of the two that has actually been through the regulatory process for a specific fat-related indication. If you're considering either compound for off-label general visceral fat reduction, GH support, or body composition outside the approved HIV lipodystrophy population, you should know you're in off-label territory with tesamorelin and in essentially untested territory with hexarelin. Off-label tesamorelin use at least borrows from a real trial dataset, even if that dataset came from a different population than you. Hexarelin use borrows from small, early studies and GH physiology in general, without a phase 3 trial to check outcomes or long-term safety against. I wouldn't reach for hexarelin as a substitute for tesamorelin based on the current evidence. If the goal is visceral fat reduction with some trial-backed safety monitoring built in, tesamorelin is the more defensible choice, and it should be used through a provider who checks IGF-1 and discusses the approved-versus-off-label distinction honestly rather than glossing over it.

Frequently asked questions

Is hexarelin FDA-approved like tesamorelin?

No. Tesamorelin is FDA-approved under the brand name Egrifta for reducing visceral abdominal fat in HIV-associated lipodystrophy, confirmed in the Drugs@FDA database. Hexarelin has no FDA approval for any human use and has not completed phase 3 trials, so there's no approved indication, dose, or safety label to reference.

Does hexarelin reduce visceral fat the same way tesamorelin does?

There's no dedicated phase 3 trial showing hexarelin reduces visceral fat the way tesamorelin's pooled phase 3 studies demonstrated. Tesamorelin's visceral fat reduction is documented in multicenter, double-blind, placebo-controlled trials. Any visceral fat claim for hexarelin is extrapolated from general GH physiology, not from a comparable human RCT.

Which is safer, hexarelin or tesamorelin?

Tesamorelin has a documented safety profile from phase 3 trials and safety extension studies, including known risks like injection site reactions, joint pain, fluid retention, and glucose effects. Hexarelin's safety data comes mostly from smaller, earlier studies without an equivalent long-term human safety database, so the honest answer is nobody has comparable long-term safety data for it.

Can tesamorelin be used for reasons other than HIV lipodystrophy?

Only off-label. Tesamorelin's FDA approval covers exactly one indication: excess visceral abdominal fat in HIV-infected patients with lipodystrophy. Using it for general fat loss, anti-aging, or bodybuilding purposes is off-label, meaning it falls outside the trial population and approved labeling, even though prescribers can legally do it.

Is hexarelin legal to buy and use?

Hexarelin isn't an FDA-approved drug, so it doesn't have an approved medical-use pathway. It circulates largely through research-chemical channels. Whether a specific sale or use is legal depends on how it's marketed and sold; buying it as a labeled research chemical for human consumption sits in a legal gray zone that a compounded, provider-prescribed tesamorelin product does not.

What does tesamorelin do to liver fat?

A randomized, double-blind, multicenter trial found tesamorelin affected non-alcoholic fatty liver disease measures in HIV patients, and separate studies linked tesamorelin-driven visceral fat reduction to improved liver enzyme levels. Follow-up research has also mapped hepatic transcriptomic and proteomic changes associated with that response.

How is tesamorelin dosed compared to hexarelin?

Tesamorelin has an FDA-approved once-daily subcutaneous dosing schedule with population pharmacokinetic data behind it in HIV-infected patients and healthy subjects. Hexarelin has no FDA-approved dose; any dosing protocol for it comes from informal or research-context sources rather than an approved label.

Does either hexarelin or tesamorelin show up on a drug test?

Both belong to classes of GH-axis stimulators that anti-doping science actively works to detect. Research on detecting GHRH synthetic analogs specifically targets this category of compound. Athletes in tested sports should assume both are treated as prohibited performance-enhancing substances.

Why does tesamorelin have so much more research than hexarelin?

Tesamorelin went through a formal FDA drug development program, including two multicenter phase 3 trials with safety extension data, because a manufacturer pursued approval for a specific indication. Hexarelin never entered that regulatory pathway, so it lacks the large, funded trial infrastructure that produces phase 3-quality evidence.

Can I get tesamorelin through a compounding pharmacy?

Yes, compounded tesamorelin is available through pharmacies operating under section 503A of the federal pharmacy compounding statute, using bulk substances that appear on FDA's 503A bulks list. This differs from buying branded Egrifta, and quality can vary by pharmacy, which is why sourcing through a provider-reviewed pathway matters.

Does tesamorelin help with cognitive function?

A 2025 study specifically examined tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity. This is an active but narrow research area within the already-narrow HIV-lipodystrophy population, not evidence for cognitive benefits in the general public.

Is hexarelin used in bodybuilding, and is that supported by evidence?

Hexarelin is used informally in bodybuilding and research-chemical circles because of its potent acute GH-releasing effect. That popularity isn't backed by phase 3 human trials or an FDA safety review, unlike tesamorelin, so the evidence supporting its use for muscle or fat goals is far weaker than the marketing around it suggests.

Sources

1. PubMed, Tesamorelin (Nature Reviews Drug Discovery, 2011): Tesamorelin is a synthetic GHRH analogue sold as Egrifta, approved for reducing visceral fat in HIV-associated lipodystrophy.
2. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (2026): Reviews of injectable GH-secretagogue peptides note the human trial evidence gap between GHRPs like hexarelin and GHRH analogues with formal drug development programs.
3. PubMed, Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (2026): Orthopaedic peptide-therapy reviews group GH secretagogues together while flagging differing levels of clinical trial support.
4. Drugs@FDA, FDA-approved drug products database: Tesamorelin is listed as FDA-approved under brand names Egrifta and Egrifta SV for reduction of visceral adipose tissue in HIV lipodystrophy.
5. FDA, bulk drug substances used in compounding under section 503A: FDA maintains and evaluates bulk drug substances for use in 503A compounding based on safety and effectiveness criteria.
6. eCFR, 21 CFR 216.23, the final 503A Bulks List: The 503A bulks list is codified in federal regulation defining which bulk substances may be compounded under that pathway.
7. eCFR, 21 CFR 216.24, the 503B Bulks List: A separate 503B bulks list governs bulk substance use for outsourcing facility compounding.
8. PubMed, pooled phase 3 tesamorelin trials (J Clin Endocrinol Metab, 2010): Two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data established tesamorelin's visceral fat reduction efficacy and safety profile.
9. PubMed, Effects of tesamorelin on NAFLD in HIV (Lancet HIV, 2019): A randomized, double-blind, multicenter trial tested tesamorelin's effects on non-alcoholic fatty liver disease in HIV patients.
10. PubMed, Visceral fat reduction with tesamorelin and liver enzymes (AIDS, 2017): Visceral fat reduction from tesamorelin was associated with improved liver enzyme levels in HIV patients.
11. PubMed, Effects of tesamorelin on inflammatory markers (AIDS, 2011): Tesamorelin's effect on inflammatory markers was studied in relation to visceral adipose reduction in HIV patients with excess abdominal fat.
12. PubMed, Effects of Tesamorelin on Neurocognitive Impairment in HIV (J Infect Dis, 2025): A 2025 study examined tesamorelin's effects on neurocognitive impairment in persons with HIV and abdominal obesity.
13. PubMed, Body composition, hepatic fat, metabolic and safety meta-analysis (Obes Res Clin Pract, 2026): A meta-analysis of randomized controlled trials pooled tesamorelin's body composition, hepatic fat, metabolic, and safety outcomes.
14. PubMed, Population pharmacokinetic analysis of tesamorelin (Clin Pharmacokinet, 2015): Population pharmacokinetic modeling characterized tesamorelin behavior in HIV-infected patients and healthy subjects.
15. PubMed, Effect of tesamorelin with/without dorsocervical fat, post hoc analysis (J Clin Transl Sci, 2023): Post hoc analysis of phase 3 trial data examined whether baseline dorsocervical fat status affected tesamorelin treatment response.
16. PubMed, Tesamorelin improves fat quality independent of fat quantity (AIDS, 2021): Tesamorelin improved fat quality measures independent of changes in overall fat quantity in a 2021 study.
17. PubMed, Tesamorelin: a review of its use in HIV-associated lipodystrophy (Drugs, 2011): Review article covers tesamorelin's efficacy and safety profile in HIV-associated lipodystrophy management.
18. PubMed, Tesamorelin: a GHRF analogue for HIV lipodystrophy (Ann Pharmacother, 2012): Pharmacotherapy review details tesamorelin's mechanism and clinical safety considerations as a GHRH analogue.
19. PubMed, Spotlight on tesamorelin in HIV-associated lipodystrophy (BioDrugs, 2011): Review summarizes tesamorelin's clinical profile and risk considerations in HIV-associated lipodystrophy.
20. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies (Sports Med, 2026): Review highlights the asymmetry in human safety and efficacy evidence between approved peptides and unapproved peptides used for musculoskeletal/athletic purposes.
21. PubMed, Effects of tesamorelin on hepatic transcriptomic signatures (JCI Insight, 2020): Study examined hepatic transcriptomic signature changes associated with tesamorelin treatment in HIV-associated NAFLD.
22. PubMed, Delineating tesamorelin response pathways in HIV-associated NAFLD (Sci Rep, 2021): Targeted proteomic and transcriptomic analysis mapped biological pathways behind tesamorelin's hepatic fat response.
23. PubMed, Advances in the detection of GHRH synthetic analogs (Drug Test Anal, 2021): Research on doping detection specifically addresses methods to identify GHRH synthetic analogs and related secretagogues.
24. Cornell Law School LII, 21 U.S.C. 353a, pharmacy compounding: Section 503A of federal law establishes the legal pathway for pharmacy compounding of drug substances, including compounded tesamorelin.